Enhertu (Trastuzumab Deruxtecan) is a next-generation antibody-drug conjugate (ADC) designed to deliver targeted cancer treatment for patients with HER2-expressing tumors. This innovative therapy combines a monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2) with a powerful topoisomerase I inhibitor, allowing the medication to deliver chemotherapy directly to cancer cells with greater precision.
Enhertu is approved for the treatment of various HER2-positive and HER2-low cancers, including metastatic breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma, and certain types of non-small cell lung cancer (NSCLC). By selectively binding to HER2 receptors on cancer cells, Enhertu is internalized into the tumor cell, where it releases its cytotoxic payload to destroy cancer cells and inhibit tumor growth.
Administered as an intravenous infusion under the supervision of healthcare professionals, Enhertu has demonstrated remarkable clinical efficacy in patients with advanced or previously treated cancers. Clinical studies have shown significant improvements in response rates and progression-free survival, making it one of the most important innovations in precision oncology and targeted cancer therapy.
As an advanced antibody-drug conjugate, Enhertu represents a major breakthrough in cancer treatment by combining targeted therapy with potent anticancer activity. Its innovative mechanism of action and expanding clinical applications continue to transform the treatment landscape for patients with HER2-expressing cancers, offering new hope and improved outcomes in modern oncology care.
Reviews
There are no reviews yet.